CF
BNGO icon

Cantor Fitzgerald’s Bionano Genomics BNGO Stock Holding History

Cantor Fitzgerald’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-917
Closed -$750K – 282
2023
Q4 		$750K Buy
917
+84
+10% +$8.77K 0.15% 76
2023
Q3 		$152K Hold
833
– – ﹤0.01% 450
2023
Q2 		$305K Buy
+833
New +$376K 0.01% 440

Other funds holding BNGO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
CA
Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cantor Fitzgerald's BNGO Position: Q1 2024 in Review

Cantor Fitzgerald sold out of Bionano Genomics (BNGO) in Q1 2024, closing a stake of 917 shares — an estimated $750K sold.

Cantor Fitzgerald first reported a position in BNGO in Q2 2023 and held it in 3 quarters. The position peaked at $750K in Q4 2023. 55 funds tracked by Wall St. Rank hold BNGO as of Q1 2024.

  • Cantor Fitzgerald reported no remaining Bionano Genomics position as of Q1 2024 after selling out during the quarter.
  • Cantor Fitzgerald sold 917 Bionano Genomics shares in Q1 2024, an estimated $750K.
  • Cantor Fitzgerald first reported a position in Bionano Genomics in Q2 2023 and held it in 3 quarters.
  • Cantor Fitzgerald's Bionano Genomics position peaked at $750K in Q4 2023.
  • 55 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2024.

Based on Cantor Fitzgerald's 13F filing for Q1 2024, filed 15 May 2024.